作为商业发展副总裁，林剑将负责领导尧唐生物BD、公共关系及投资者关系部的整体管理，根据公司总体战略发展需要，负责制定及执行伙伴关系及企业投资策略、建立创新能力以及整体相关业务生态系统，通过合作为公司带来优质的研发及商业资源和投资机会，推动公司业务增长。

林剑本科毕业于山东大学国家生物基地班生物技术专业，拥有中国科学院生物技术与医药专业硕士学位和中欧商学院MBA，法国蒙彼利埃大学就读医药健康管理学博士。

在加入尧唐生物之前，林剑曾在康宁杰瑞担任商务合作部门负责人，负责公司全球BD以及战略联盟管理业务；并曾服务于多家跨国制药企业包括日本卫材、勃林格殷格翰、强生和诺华等公司，在商务拓展、战略制定、投资并购、联盟管理、市场销售及产品管理领域积累了丰富的经验。

林剑在生物制药行业经验超过15年，他曾主导并参与20多项国内及全球对外合作，涵盖license许可交易、战略合作以及股权交易等多种商业模式，总交易金额超过10亿美金，维护并管理数十家全球合作伙伴关系包括辉瑞、赛诺菲、德国默克、中国石药、先声、以岭及京东健康等知名企业。

As Vice President of Business Development, Colin Lin will be responsible for leading the overall BD, public relations, and investor relations departments in Yoltech, he will bring high-quality R&D and commercial resources and investment opportunities to the company through various of partnership including out-licensing and financing,  to empower pipeline competence and promote business growth.

Colin started career from Novartis internship and then got MT offer from Johnson & Johnson Medical. Led multiple healthcare licensing, strategy, and equity projects in Eisai. Acted as brand owner of company’s best selling product in Boehringer Ingelheim. As head of BD at Alphamab, led 10+ deals, including inlicensing, global out-licensing, and multi-spectrum deals (total deal size nearly $1.0 Bn). 

Colin has 15 years of  pharmaceutical industry experience in business development, strategy & alliance management, etc. Led to complete a number of licensing deals, strategic cooperation and equity investment projects, owned a wealth of experience across all parts of business development value chain, familiar with various of disease fields. He is PhD candidate in montpellieruniversity, received a master's degree in biomedicine from the China Academy of Science and a MBA degree in CEIBS.